An Application of Computational Drug Repurposing Based on Transcriptomic Signatures.

Drug repurposing is a methodology where already existing drugs are tested against diseases outside their initial usage, in order to reduce the high cost and long periods of new drug development. In silico drug repurposing further speeds up the process, by testing a large number of drugs against the biological signatures of known diseases. In this chapter, we present a step-by-step methodology of a transcriptomics-based computational drug repurposing pipeline providing a comprehensive guide to the whole procedure, from proper dataset selection to short list derivation of repurposed drugs which might act as inhibitors against the studied disease. The presented pipeline contains the selection and curation of proper transcriptomics datasets, statistical analysis of the datasets in order to extract the top over- and under-expressed gene identifiers, appropriate identifier conversion, drug repurposing analysis, repurposed drugs filtering, cross-tool screening, drug-list re-ranking, and results' validation.

[1]  Ross Ihaka,et al.  Gentleman R: R: A language for data analysis and graphics , 1996 .

[2]  G. Spyrou,et al.  Drug repurposing in idiopathic pulmonary fibrosis filtered by a bioinformatics-derived composite score , 2017, Scientific Reports.

[3]  Ibrahim Emam,et al.  ArrayExpress update—an archive of microarray and high-throughput sequencing-based functional genomics experiments , 2010, Nucleic Acids Res..

[4]  Florian Hahne,et al.  QuasR: quantification and annotation of short reads in R , 2015, Bioinform..

[5]  Mark D. Robinson,et al.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..

[6]  Angela N. Brooks,et al.  A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles , 2017, Cell.

[7]  Ravi Iyengar,et al.  The Library of Integrated Network-Based Cellular Signatures NIH Program: System-Level Cataloging of Human Cells Response to Perturbations. , 2017, Cell systems.

[8]  Alex E. Lash,et al.  Gene Expression Omnibus: NCBI gene expression and hybridization array data repository , 2002, Nucleic Acids Res..

[9]  Guoying Liu,et al.  NetAffx: Affymetrix probesets and annotations , 2003, Nucleic Acids Res..

[10]  Günter Klambauer,et al.  DeepTox: Toxicity Prediction using Deep Learning , 2016, Front. Environ. Sci..

[11]  Jerry Avorn,et al.  The $2.6 billion pill--methodologic and policy considerations. , 2015, The New England journal of medicine.

[12]  Olivier Michielin,et al.  SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules , 2017, Scientific Reports.

[13]  Chirag J. Patel,et al.  A review of validation strategies for computational drug repositioning , 2016, Briefings Bioinform..

[14]  Kimberly R. Kukurba,et al.  RNA Sequencing and Analysis. , 2015, Cold Spring Harbor protocols.

[15]  Charles C. Persinger,et al.  How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.

[16]  Gang Fu,et al.  PubChem Substance and Compound databases , 2015, Nucleic Acids Res..

[17]  David S. Wishart,et al.  DrugBank: a comprehensive resource for in silico drug discovery and exploration , 2005, Nucleic Acids Res..

[18]  Emmanouil Athanasiadis,et al.  ChemBioServer: a web-based pipeline for filtering, clustering and visualization of chemical compounds used in drug discovery , 2012, Bioinform..

[19]  Junjun Zhang,et al.  BioMart Central Portal—unified access to biological data , 2009, Nucleic Acids Res..

[20]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[21]  Nikolas Dovrolis,et al.  Laying in silico pipelines for drug repositioning: a paradigm in ensemble analysis for neurodegenerative diseases. , 2017, Drug discovery today.

[22]  Jean YH Yang,et al.  Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.

[23]  Chris Morley,et al.  Open Babel: An open chemical toolbox , 2011, J. Cheminformatics.

[24]  Marc Hafner,et al.  L1000CDS2: LINCS L1000 characteristic direction signatures search engine , 2016, npj Systems Biology and Applications.

[25]  Steven Simoens,et al.  A comparative study of European rare disease and orphan drug markets. , 2010, Health policy.

[26]  P. Bork,et al.  A side effect resource to capture phenotypic effects of drugs , 2010, Molecular systems biology.

[27]  Philip E. Bourne,et al.  PROMISCUOUS: a database for network-based drug-repositioning , 2010, Nucleic Acids Res..

[28]  Paul A Clemons,et al.  The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.